HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission.
The filing can be viewed through a link on FibroBiologics’ website at https://ir.fibrobiologics.com/sec-filings/quarterly-reports.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.58 |
| Daily Change: | -0.23 -8.19 |
| Daily Volume: | 262,325 |
| Market Cap: | US$90.970M |
November 12, 2024 October 18, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
